Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Millions of people struggle with weight management, and GLP-1 receptor agonists have become a game-changing option for sustainable weight loss. Unlike many telehealth providers, PlexusDx serves all 50 states with compounded medications from licensed 503A pharmacies, making eligibility straightforward and accessibility real.

Core GLP-1 Eligibility Requirements

GLP-1 therapy is appropriate for adults with a BMI of 30 or higher, or those with a BMI of 27 or higher who also have weight-related health conditions such as type 2 diabetes, high blood pressure, or heart disease risk factors. Clinical trials demonstrate that GLP-1 medications reduce body weight by 15-22% over 68 weeks, making them one of the most effective weight loss tools available. PlexusDx reviews your health history during a simple online consultation to determine if you meet these evidence-based criteria.

Age matters: you must be 18 or older to receive GLP-1 therapy. Pregnancy and active plans to become pregnant are contraindications because safety data in pregnant populations remains limited. PlexusDx providers ask about your medical history, current medications, and weight loss goals to ensure GLP-1 is safe and appropriate for your unique situation.

Medical Conditions That Support GLP-1 Eligibility

Certain health conditions make GLP-1 therapy especially valuable and increase your eligibility pathway. Type 2 diabetes, hypertension, sleep apnea, joint pain from excess weight, and high cholesterol all respond favorably when combined with GLP-1 treatment. Studies show GLP-1 users experience improvements in blood sugar control, blood pressure, and cardiovascular markers alongside weight loss.

A personal or family history of heart disease, stroke, or metabolic syndrome strengthens the case for GLP-1 therapy in clinical practice. PlexusDx providers consider your complete health picture because GLP-1 medications address both weight and underlying metabolic dysfunction simultaneously. You do not need a diagnosis of type 2 diabetes to qualify; weight-related health risks alone support eligibility.

How PlexusDx Determines Your GLP-1 Eligibility

PlexusDx uses a streamlined online assessment process that avoids lengthy office visits and insurance delays. You complete a comprehensive health questionnaire covering weight history, past diets, current medications, allergies, and health conditions. A licensed provider reviews your information, verifies your eligibility, and discusses which GLP-1 option—semaglutide injection starting at $149/mo, oral semaglutide, tirzepatide, or dual-compound GLP-Squared—aligns with your goals.

No insurance is required, and HSA and FSA accounts cover PlexusDx medications, reducing out-of-pocket costs. The entire process takes days, not weeks, so eligible patients can begin treatment quickly. PlexusDx operates in all 50 states, eliminating geographic barriers that disqualify patients at traditional clinics.

Genetic Testing and Personalized GLP-1 Response

Not everyone responds identically to GLP-1 medications, and genetics help explain why. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after your first month) to map 14 metabolic pathways, 49 peptides, and 150+ genetic insights related to weight regulation and GLP-1 response. Key variants in genes like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 influence how your body processes appetite signals and metabolic hormones.

This peptide-pathway genetic test identifies whether you carry genetic predispositions favoring stronger GLP-1 response, altered appetite sensitivity, or specific fat storage patterns. Armed with this data, PlexusDx providers personalize your medication choice, dosing strategy, and expected timeline to goal weight. Eligibility becomes not just whether you can take GLP-1, but which GLP-1 formulation will work best for your unique biology.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Do I need a diabetes diagnosis to be eligible for GLP-1 therapy with PlexusDx?

No. PlexusDx prescribes GLP-1 medications to people without diabetes if they have a BMI of 30 or higher, or a BMI of 27 or higher with weight-related health conditions. Weight loss and metabolic improvement are valid clinical goals independent of diabetes status.

What is the minimum BMI to qualify for GLP-1 at PlexusDx?

The standard threshold is a BMI of 30. However, if your BMI is 27-29.9 and you have conditions like high blood pressure, sleep apnea, heart disease risk, or type 2 diabetes, you typically qualify. PlexusDx providers assess your individual health profile during consultation.

Can I get GLP-1 therapy if I have a history of thyroid cancer or pancreatitis?

Personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 are contraindications to GLP-1 therapy due to black box warnings. A history of pancreatitis requires careful assessment by your PlexusDx provider. Always disclose complete medical history during your consultation.

How much does GLP-1 treatment cost at PlexusDx, and does price change with dose increases?

Compounded Semaglutide Injection starts at $149/mo flat—your dose may need to go up, but your price won't. Oral semaglutide begins at $249/mo, and tirzepatide options range from $249-$279/mo depending on formulation. HSA and FSA accounts cover all medications, and no insurance is required.

What does the Precision Peptide Genetic Test reveal about my GLP-1 eligibility?

The test doesn't determine eligibility itself, but it reveals genetic predispositions in weight-regulation pathways like GLP1R, GIPR, FTO, and MC4R. This helps PlexusDx providers predict your likely response to GLP-1, optimize medication choice, and set realistic timeline expectations for your weight loss journey.

Can I be eligible for GLP-1 if I take other weight loss medications?

Combining GLP-1 with other weight loss drugs requires careful evaluation by your PlexusDx provider. Drug interactions and overlapping mechanisms must be considered. Always disclose all current medications during your consultation so providers can make safe recommendations.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves